Asunercept

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Asunercept

Accession Number

DB15160

Description

Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).

Type

Biotech

Groups

Investigational

Purchasing individual compounds or compound libraries for your research?

Learn More

Synonyms

Not Available

External IDs

APG101

Pharmacology

Indication: Not Available
Contraindications & Blackbox Warnings: Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics: Not Available
Mechanism of action: Not Available
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half-life: Not Available
Clearance: Not Available
Adverse Effects: Learn about our commercial Adverse Effects data.
Learn More
Toxicity: Not Available
Affected organisms: Not Available
Pathways: Not Available
Pharmacogenomic Effects/ADRs: Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Abciximab	The risk or severity of adverse effects can be increased when Abciximab is combined with Asunercept.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Asunercept.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Asunercept.
Alirocumab	The risk or severity of adverse effects can be increased when Alirocumab is combined with Asunercept.
Anthrax immune globulin human	The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Asunercept.
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Asunercept.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Asunercept.
Asfotase alfa	The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Asunercept.
Atezolizumab	The risk or severity of adverse effects can be increased when Atezolizumab is combined with Asunercept.
Atoltivimab	The risk or severity of adverse effects can be increased when Asunercept is combined with Atoltivimab.

Additional Data Available

Extended Description

Available for Purchase

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

Available for Purchase

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

Available for Purchase

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

Available for Purchase

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

Chemical Identifiers

UNII: F333OQQ9UV
CAS number: 1450882-18-4

References

General References

Not Available

External Links

Wikipedia: Asunercept

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Glioblastoma Multiforme (GBM)	1
2	Recruiting	Treatment	COVID-19 Induced Pneumonia / Novel Coronavirus Infectious Disease (COVID-19)	1
1	Completed	Treatment	Glioblastoma Multiforme (GBM)	1
1	Completed	Treatment	Myelodysplastic Syndrome	1
1, 2	Recruiting	Treatment	Glioblastoma, Adult	1